印度醇衍生物对急性Toxoplasma gondii感染的肠道屏障保护作用
Jieqiong Wang1, Weifeng Yan1, Xu Cheng1
1Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China.
Molecules (Basel, Switzerland)
|November 9, 2024
概括
新的醇衍生物在保护肠道屏障免受Toxoplasma gondii感染方面表现有前途. 这些化合物增强了肠道健康,并为毒素菌提供了潜在的新疗法.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 免疫学 免疫学 免疫学
背景情况:
- 毒素菌 (T. gondii) 引起的毒素菌是一种重要的动物性传染病.
- 目前的毒素菌治疗方法不能有效地修复肠道屏障损伤,这是一个关键的漏洞.
- 肠道屏障对于防御T. gondii的入侵至关重要.
研究的目的:
- 研究新型醇衍生物对患有急性T. gondii感染的小鼠肠道屏障的保护作用.
- 探索这些衍生物的潜力,作为治疗毒素引起的肠损伤的治疗剂.
主要方法:
- 使用Vilsmeier-Haack反应合成醇化物衍生物.
- 在体外和体内对肠道屏障保护作用的评估.
- 评估胃肠道运动性,抗氧化剂水平 (谷氨) 和氧化应激标志物 (甲,氧化).
- 对抗T. gondii活性和分子对接研究的评估.
主要成果:
- 一些醇衍生物,特别是A3 (醇-3-碳酸),与螺旋相比,具有更高的选择性.
- 这些衍生品改善了胃肠道的运动性,增加了谷氨,并降低了甲和氧化的水平.
- 衍生品A3表现出抗T. gondii tachyzoites活性和与寄生虫酶的有利分子相互作用.
结论:
- 印度醇化物衍生物显示出保护肠道屏障免受T. gondii感染的显著潜力.
- 衍生物A3是进一步开发作为毒素菌治疗剂的有希望的候选物.
- 这项研究为治疗肠道屏障损伤提供了一种新的策略,并促进对T. gondii感染的药物开发.
更多相关视频
11:21Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity
Published on: March 12, 2015
11.0K
09:49Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
Published on: April 29, 2020
7.1K
相关概念视频
Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
